Boston Partners Cuts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Boston Partners lowered its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 38.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,631,076 shares of the medical equipment provider's stock after selling 1,004,496 shares during the period. Boston Partners owned about 0.82% of Zimmer Biomet worth $172,312,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of ZBH. Atria Investments Inc raised its holdings in shares of Zimmer Biomet by 60.2% during the 3rd quarter. Atria Investments Inc now owns 5,429 shares of the medical equipment provider's stock worth $586,000 after buying an additional 2,041 shares in the last quarter. KBC Group NV boosted its position in shares of Zimmer Biomet by 64.0% during the 3rd quarter. KBC Group NV now owns 25,287 shares of the medical equipment provider's stock valued at $2,730,000 after purchasing an additional 9,864 shares in the last quarter. CIBC Asset Management Inc boosted its position in shares of Zimmer Biomet by 7.4% during the 3rd quarter. CIBC Asset Management Inc now owns 29,718 shares of the medical equipment provider's stock valued at $3,208,000 after purchasing an additional 2,039 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Zimmer Biomet by 6.8% during the 3rd quarter. Empowered Funds LLC now owns 4,135 shares of the medical equipment provider's stock valued at $446,000 after purchasing an additional 265 shares in the last quarter. Finally, Natixis Advisors LLC raised its stake in Zimmer Biomet by 24.7% during the 3rd quarter. Natixis Advisors LLC now owns 63,651 shares of the medical equipment provider's stock worth $6,871,000 after buying an additional 12,602 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Remove Ads

Zimmer Biomet Price Performance

ZBH stock traded down $0.99 during mid-day trading on Friday, hitting $110.79. 2,942,594 shares of the stock were exchanged, compared to its average volume of 1,498,375. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The business has a fifty day moving average price of $106.74 and a 200 day moving average price of $106.86. The stock has a market capitalization of $22.05 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the firm posted $2.20 earnings per share. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet's dividend payout ratio is presently 21.57%.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZBH. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays dropped their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Truist Financial reissued a "hold" rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Raymond James reduced their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $124.15.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.